The global in vivo cell therapy market size was valued at USD 229.2 million in 2025 and is projected to grow from USD 340.7 million in 2026 toUSD 5.72 billion by 2033, at a CAGR of 49.6% from 2026 to 2033. North America dominated the global market, accounting for the largest revenue share of 55.9% in 2025. The investment in vivo cell therapy development, advances in targeted delivery technologies, and growing adoption of programmable cell-engineering approaches for precision medicine.
Global In Vivo Cell Therapy Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, the analyst has segmented the global in vivo cell therapy industry on the basis of therapeutic cell type, therapeutic application, in vivo cell-engineering, delivery modality, and regionTherapeutic Cell Type Outlook (Revenue, USD Million, 2021 - 2033)
- T Cells
- NK Cells
- Myeloid Cells
- Other Immune Cells
Therapeutic Application Outlook (Revenue, USD Million, 2021 - 2033)
- Hematological Malignancies
- Solid Tumors
- Autoimmune Disease
- Infectious Disease
- Other Therapeutic Applications
In Vivo Cell- Engineering Outlook (Revenue, USD Million, 2021 - 2033)
- Receptor Engineering
- Gene Editing & Gene Modification
- Transient Genetic Programming
- Other Cell -Engineering Approaches
Delivery Modality Outlook (Revenue, USD Million, 2021 - 2033)
- Viral Vector-based
- Lipid Nanoparticle-based
- Other Non-viral Delivery System
Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Therapeutic Cell Type
1.1.1.2. Therapeutic Application
1.1.1.3. In Vivo Cell-Engineering
1.1.1.4. Delivery Modality
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. The internal database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis:
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. List of Secondary Sources
1.9.3. List of Abbreviations
1.1.1. Segment Definitions
1.1.1.1. Therapeutic Cell Type
1.1.1.2. Therapeutic Application
1.1.1.3. In Vivo Cell-Engineering
1.1.1.4. Delivery Modality
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. The internal database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis:
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. List of Secondary Sources
1.9.3. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Investment in In Vivo Cell Therapy Development
3.2.1.2. Advances in Targeted Delivery Technologies
3.2.1.3. Expansion of Programmable Cell Therapies for Precision Medicine
3.2.2. Market Restraint Analysis
3.2.2.1. Challenges in Achieving Precise and Targeted Delivery
3.2.2.2. Regulatory Uncertainty for In Vivo Cell Therapies
3.2.3. Market Opportunities Analysis
3.2.4. Market Challenges Analysis
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Social landscape
3.3.2.4. Economic landscape
3.3.2.5. Legal landscape
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Investment in In Vivo Cell Therapy Development
3.2.1.2. Advances in Targeted Delivery Technologies
3.2.1.3. Expansion of Programmable Cell Therapies for Precision Medicine
3.2.2. Market Restraint Analysis
3.2.2.1. Challenges in Achieving Precise and Targeted Delivery
3.2.2.2. Regulatory Uncertainty for In Vivo Cell Therapies
3.2.3. Market Opportunities Analysis
3.2.4. Market Challenges Analysis
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Social landscape
3.3.2.4. Economic landscape
3.3.2.5. Legal landscape
Chapter 4. Therapeutic Cell Type Business Analysis
4.1. Segment Dashboard
4.2. In Vivo Cell Therapy Market: Therapeutic Cell Type Movement Analysis
4.2.1. T Cells
4.2.2. T Cells Market, 2021 - 2033 (USD Million)
4.2.3. NK Cells
4.2.4. NK Cells Kits Market, 2021 - 2033 (USD Million)
4.2.5. Myeloid Cells
4.2.6. Myeloid Cells Market, 2021 - 2033 (USD Million)
4.3. Other Immune Cells
4.3.1. Other Immune Cells Market, 2021 - 2033 (USD Million)
4.2. In Vivo Cell Therapy Market: Therapeutic Cell Type Movement Analysis
4.2.1. T Cells
4.2.2. T Cells Market, 2021 - 2033 (USD Million)
4.2.3. NK Cells
4.2.4. NK Cells Kits Market, 2021 - 2033 (USD Million)
4.2.5. Myeloid Cells
4.2.6. Myeloid Cells Market, 2021 - 2033 (USD Million)
4.3. Other Immune Cells
4.3.1. Other Immune Cells Market, 2021 - 2033 (USD Million)
Chapter 5. Therapeutic Application Business Analysis
5.1. Segment Dashboard
5.2. In Vivo Cell Therapy Market: Therapeutic Application Movement Analysis
5.3. Hematological Malignancies
5.3.1. Hematological Malignancies Market, 2021 - 2033 (USD Million)
5.4. Solid Tumors
5.4.1. Solid Tumors Market, 2021 - 2033 (USD Million)
5.5. Autoimmune Diseases
5.5.1. Autoimmune Diseases Market, 2021 - 2033 (USD Million)
5.6. Infectious Diseases
5.6.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
5.7. Other Therapeutic Applications
5.7.1. Other Therapeutic Applications Market, 2021 - 2033 (USD Million)
5.2. In Vivo Cell Therapy Market: Therapeutic Application Movement Analysis
5.3. Hematological Malignancies
5.3.1. Hematological Malignancies Market, 2021 - 2033 (USD Million)
5.4. Solid Tumors
5.4.1. Solid Tumors Market, 2021 - 2033 (USD Million)
5.5. Autoimmune Diseases
5.5.1. Autoimmune Diseases Market, 2021 - 2033 (USD Million)
5.6. Infectious Diseases
5.6.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
5.7. Other Therapeutic Applications
5.7.1. Other Therapeutic Applications Market, 2021 - 2033 (USD Million)
Chapter 6. In Vivo Cell-Engineering Business Analysis
6.1. Segment Dashboard
6.2. In Vivo Cell Therapy Market: In Vivo Cell-Engineering Movement Analysis
6.3. Receptor Engineering
6.3.1. Receptor Engineering Market, 2021 - 2033 (USD Million)
6.4. Gene Editing & Gene Modification
6.4.1. Gene Editing & Gene Modification Market, 2021 - 2033 (USD Million)
6.5. Transient Genetic Programming
6.5.1. Transient Genetic Programming Market, 2021 - 2033 (USD Million)
6.6. Other Cell-Engineering Approaches
6.6.1. Other Cell-Engineering Approaches Market, 2021 - 2033 (USD Million)
6.2. In Vivo Cell Therapy Market: In Vivo Cell-Engineering Movement Analysis
6.3. Receptor Engineering
6.3.1. Receptor Engineering Market, 2021 - 2033 (USD Million)
6.4. Gene Editing & Gene Modification
6.4.1. Gene Editing & Gene Modification Market, 2021 - 2033 (USD Million)
6.5. Transient Genetic Programming
6.5.1. Transient Genetic Programming Market, 2021 - 2033 (USD Million)
6.6. Other Cell-Engineering Approaches
6.6.1. Other Cell-Engineering Approaches Market, 2021 - 2033 (USD Million)
Chapter 7. Delivery Modality Business Analysis
7.1. Segment Dashboard
7.2. In Vivo Cell Therapy Market: Delivery Modality Movement Analysis
7.3. Viral Vector-based
7.3.1. Viral Vector-based Market, 2021 - 2033 (USD Million)
7.4. Lipid Nanoparticle-based
7.4.1. Lipid Nanoparticle-based Market, 2021 - 2033 (USD Million)
7.5. Other Non-viral Delivery Systems
7.5.1. Other Non-viral Delivery Systems Market, 2021 - 2033 (USD Million)
7.2. In Vivo Cell Therapy Market: Delivery Modality Movement Analysis
7.3. Viral Vector-based
7.3.1. Viral Vector-based Market, 2021 - 2033 (USD Million)
7.4. Lipid Nanoparticle-based
7.4.1. Lipid Nanoparticle-based Market, 2021 - 2033 (USD Million)
7.5. Other Non-viral Delivery Systems
7.5.1. Other Non-viral Delivery Systems Market, 2021 - 2033 (USD Million)
Chapter 8. Regional Business Analysis
8.1. In Vivo Cell Therapy Market Share by Region, 2025 & 2033
8.2. North America
8.2.1. North America In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Competitive Scenario
8.2.2.3. Regulatory Framework
8.2.2.4. U.S. In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Competitive Scenario
8.2.3.3. Regulatory Framework
8.2.3.4. Canada In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.2.4. Mexico
8.2.4.1. Key Country Dynamics
8.2.4.2. Competitive Scenario
8.2.4.3. Regulatory Framework
8.2.4.4. Mexico In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3. Europe
8.3.1. Europe In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.2. UK
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. UK In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Germany In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. France In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Regulatory Framework
8.3.5.4. Italy In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Competitive Scenario
8.3.6.3. Regulatory Framework
8.3.6.4. Spain In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Competitive Scenario
8.3.7.3. Regulatory Framework
8.3.7.4. Denmark In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Competitive Scenario
8.3.8.3. Regulatory Framework
8.3.8.4. Sweden In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Competitive Scenario
8.3.9.3. Regulatory Framework
8.3.9.4. Norway In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. Japan In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. China In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. India In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.5. Australia
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. Australia In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.6. Thailand
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Thailand In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.7. South Korea
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. South Korea In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.5. Latin America
8.5.1. Latin America In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Brazil In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.5.3. Argentina
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Argentina In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.6. MEA
8.6.1. MEA In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. South Africa In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Saudi Arabia In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. UAE In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Kuwait In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.2. North America
8.2.1. North America In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Competitive Scenario
8.2.2.3. Regulatory Framework
8.2.2.4. U.S. In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Competitive Scenario
8.2.3.3. Regulatory Framework
8.2.3.4. Canada In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.2.4. Mexico
8.2.4.1. Key Country Dynamics
8.2.4.2. Competitive Scenario
8.2.4.3. Regulatory Framework
8.2.4.4. Mexico In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3. Europe
8.3.1. Europe In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.2. UK
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. UK In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Germany In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. France In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Regulatory Framework
8.3.5.4. Italy In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Competitive Scenario
8.3.6.3. Regulatory Framework
8.3.6.4. Spain In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Competitive Scenario
8.3.7.3. Regulatory Framework
8.3.7.4. Denmark In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Competitive Scenario
8.3.8.3. Regulatory Framework
8.3.8.4. Sweden In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Competitive Scenario
8.3.9.3. Regulatory Framework
8.3.9.4. Norway In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. Japan In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. China In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. India In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.5. Australia
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. Australia In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.6. Thailand
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Thailand In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.4.7. South Korea
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. South Korea In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.5. Latin America
8.5.1. Latin America In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Brazil In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.5.3. Argentina
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Argentina In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.6. MEA
8.6.1. MEA In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. South Africa In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Saudi Arabia In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. UAE In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Kuwait In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Company Market Share/ Position Analysis, 2025
9.3. Strategy Mapping
9.4. Company Profiles/Listing
9.4.1. Gilead Sciences, Inc.
9.4.1.1. Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Legend Biotech
9.4.2.1. Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Eli Lilly and Company
9.4.3.1. Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. CRISPR Therapeutics
9.4.4.1. Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. AbbVie Inc.
9.4.5.1. Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Umoja Biopharma
9.4.6.1. Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Ensoma, Inc.
9.4.7.1. Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. Intellia Therapeutics, Inc.
9.4.8.1. Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. Tessera Therapeutics
9.4.9.1. Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. AstraZeneca
9.4.10.1. Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
9.4.11. Johnson & Johnson
9.4.11.1. Overview
9.4.11.2. Financial Performance
9.4.11.3. Product Benchmarking
9.4.11.4. Strategic Initiatives
9.4.12. Valerio Therapeutics
9.4.12.1. Overview
9.4.12.2. Financial Performance
9.4.12.3. Product Benchmarking
9.4.12.4. Strategic Initiatives
9.2. Company Market Share/ Position Analysis, 2025
9.3. Strategy Mapping
9.4. Company Profiles/Listing
9.4.1. Gilead Sciences, Inc.
9.4.1.1. Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Legend Biotech
9.4.2.1. Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Eli Lilly and Company
9.4.3.1. Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. CRISPR Therapeutics
9.4.4.1. Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. AbbVie Inc.
9.4.5.1. Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Umoja Biopharma
9.4.6.1. Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Ensoma, Inc.
9.4.7.1. Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. Intellia Therapeutics, Inc.
9.4.8.1. Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. Tessera Therapeutics
9.4.9.1. Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. AstraZeneca
9.4.10.1. Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
9.4.11. Johnson & Johnson
9.4.11.1. Overview
9.4.11.2. Financial Performance
9.4.11.3. Product Benchmarking
9.4.11.4. Strategic Initiatives
9.4.12. Valerio Therapeutics
9.4.12.1. Overview
9.4.12.2. Financial Performance
9.4.12.3. Product Benchmarking
9.4.12.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 4 Global in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 5 Global in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 6 Global in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 7 Global in vivo cell therapy market, region, 2021 - 2033 (USD million)
Table 8 North America in vivo cell therapy market, country, 2021 - 2033 (USD million)
Table 9 North America in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 10 North America in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 11 North America in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 12 North America in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 13 U.S. in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 14 U.S. in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 15 U.S. in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 16 U.S. in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 17 Canada in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 18 Canada in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 19 Canada in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 20 Canada in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 21 Mexico in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 22 Mexico in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 23 Mexico in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 24 Mexico in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 25 Europe in vivo cell therapy market, country, 2021 - 2033 (USD million)
Table 26 Europe in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 27 Europe in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 28 Europe in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 29 Europe in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 30 UK in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 31 UK in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 32 UK in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 33 UK in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 34 Germany in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 35 Germany in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 36 Germany in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 37 Germany in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 38 France in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 39 France in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 40 France in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 41 France in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 42 Italy in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 43 Italy in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 44 Italy in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 45 Italy in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 46 Spain in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 47 Spain in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 48 Spain in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 49 Spain in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 50 Denmark in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 51 Denmark in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 52 Denmark in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 53 Denmark in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 54 Sweden in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 55 Sweden in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 56 Sweden in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 57 Sweden in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 58 Norway in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 59 Norway in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 60 Norway in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 61 Norway in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 62 Asia Pacific in vivo cell therapy market, country, 2021 - 2033 (USD million)
Table 63 Asia Pacific in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 64 Asia Pacific in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 65 Asia Pacific in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 66 Asia Pacific in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 67 Japan in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 68 Japan in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 69 Japan in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 70 Japan in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 71 China in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 72 China in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 73 China in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 74 China in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 75 India in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 76 India in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 77 India in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 78 India in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 79 Australia in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 80 Australia in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 81 Australia in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 82 Australia in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 83 Thailand in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 84 Thailand in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 85 Thailand in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 86 Thailand in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 87 South Korea in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 88 South Korea in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 89 South Korea in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 90 South Korea in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 91 Latin America in vivo cell therapy market, country, 2021 - 2033 (USD million)
Table 92 Latin America in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 93 Latin America in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 94 Latin America in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 95 Latin America in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 96 Brazil in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 97 Brazil in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 98 Brazil in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 99 Brazil in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 100 Argentina in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 101 Argentina in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 102 Argentina in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 103 Argentina in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 104 Middle East & Africa in vivo cell therapy market, country, 2021 - 2033 (USD million)
Table 105 Middle East & Africa in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 106 Middle East & Africa in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 107 Middle East & Africa in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 108 Middle East & Africa in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 109 South Africa in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 110 South Africa in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 111 South Africa in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 112 South Africa in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 113 Saudi Arabia in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 114 Saudi Arabia in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 115 Saudi Arabia in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 116 Saudi Arabia in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 117 UAE in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 118 UAE in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 119 UAE in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 120 UAE in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 121 Kuwait in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 122 Kuwait in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 123 Kuwait in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 124 Kuwait in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 2 List of abbreviations
Table 3 Global in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 4 Global in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 5 Global in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 6 Global in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 7 Global in vivo cell therapy market, region, 2021 - 2033 (USD million)
Table 8 North America in vivo cell therapy market, country, 2021 - 2033 (USD million)
Table 9 North America in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 10 North America in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 11 North America in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 12 North America in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 13 U.S. in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 14 U.S. in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 15 U.S. in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 16 U.S. in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 17 Canada in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 18 Canada in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 19 Canada in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 20 Canada in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 21 Mexico in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 22 Mexico in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 23 Mexico in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 24 Mexico in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 25 Europe in vivo cell therapy market, country, 2021 - 2033 (USD million)
Table 26 Europe in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 27 Europe in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 28 Europe in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 29 Europe in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 30 UK in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 31 UK in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 32 UK in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 33 UK in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 34 Germany in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 35 Germany in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 36 Germany in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 37 Germany in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 38 France in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 39 France in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 40 France in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 41 France in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 42 Italy in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 43 Italy in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 44 Italy in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 45 Italy in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 46 Spain in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 47 Spain in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 48 Spain in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 49 Spain in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 50 Denmark in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 51 Denmark in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 52 Denmark in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 53 Denmark in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 54 Sweden in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 55 Sweden in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 56 Sweden in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 57 Sweden in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 58 Norway in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 59 Norway in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 60 Norway in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 61 Norway in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 62 Asia Pacific in vivo cell therapy market, country, 2021 - 2033 (USD million)
Table 63 Asia Pacific in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 64 Asia Pacific in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 65 Asia Pacific in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 66 Asia Pacific in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 67 Japan in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 68 Japan in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 69 Japan in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 70 Japan in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 71 China in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 72 China in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 73 China in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 74 China in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 75 India in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 76 India in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 77 India in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 78 India in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 79 Australia in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 80 Australia in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 81 Australia in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 82 Australia in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 83 Thailand in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 84 Thailand in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 85 Thailand in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 86 Thailand in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 87 South Korea in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 88 South Korea in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 89 South Korea in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 90 South Korea in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 91 Latin America in vivo cell therapy market, country, 2021 - 2033 (USD million)
Table 92 Latin America in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 93 Latin America in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 94 Latin America in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 95 Latin America in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 96 Brazil in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 97 Brazil in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 98 Brazil in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 99 Brazil in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 100 Argentina in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 101 Argentina in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 102 Argentina in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 103 Argentina in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 104 Middle East & Africa in vivo cell therapy market, country, 2021 - 2033 (USD million)
Table 105 Middle East & Africa in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 106 Middle East & Africa in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 107 Middle East & Africa in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 108 Middle East & Africa in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 109 South Africa in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 110 South Africa in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 111 South Africa in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 112 South Africa in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 113 Saudi Arabia in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 114 Saudi Arabia in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 115 Saudi Arabia in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 116 Saudi Arabia in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 117 UAE in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 118 UAE in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 119 UAE in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 120 UAE in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
Table 121 Kuwait in vivo cell therapy market, therapeutic cell type, 2021 - 2033 (USD million)
Table 122 Kuwait in vivo cell therapy market, therapeutic application, 2021 - 2033 (USD million)
Table 123 Kuwait in vivo cell therapy market, in vivo cell-engineering, 2021 - 2033 (USD million)
Table 124 Kuwait in vivo cell therapy market, delivery modality, 2021 - 2033 (USD million)
List of Figures
Fig. 1 In Vivo Cell Therapy market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Market formulation & validation
Figure 7 Market outlook
Figure 8 Segment snapshot
Figure 9 Competitive landscape snapshot
Figure 10 Parent market outlook
Figure 11 In Vivo Cell Therapy market driver analysis
Figure 12 In Vivo Cell Therapy market restraint analysis
Figure 13 In Vivo Cell Therapy market: Porter's five forces analysis
Figure 14 In Vivo Cell Therapy market: PESTLE analysis
Figure 15 In Vivo Cell Therapy market: therapeutic cell type outlook and key takeaways
Figure 16 In Vivo Cell Therapy market: therapeutic cell type market share analysis
Figure 17 T cells market, 2021 - 2033 (USD million)
Figure 18 NK cells market, 2021 - 2033 (USD million)
Figure 19 Myeloid cells market, 2021 - 2033 (USD million)
Figure 20 Other immune cells market, 2021 - 2033 (USD million)
Figure 21 In Vivo Cell Therapy market: therapeutic application outlook and key takeaways
Figure 22 In Vivo Cell Therapy market: therapeutic application market share analysis
Figure 23 Hematological malignancies market, 2021 - 2033 (USD million)
Figure 24 Solid tumors market, 2021 - 2033 (USD million)
Figure 25 Autoimmune diseases market, 2021 - 2033 (USD million)
Figure 26 Infectious diseases market, 2021 - 2033 (USD million)
Figure 27 Other therapeutic applications market, 2021 - 2033 (USD million)
Figure 28 In Vivo Cell Therapy market: in vivo cell-engineering outlook and key takeaways
Figure 29 In Vivo Cell Therapy market: in vivo cell-engineering market share analysis
Figure 30 Receptor engineering market, 2021 - 2033 (USD million)
Figure 31 Gene editing & gene modification market, 2021 - 2033 (USD million)
Figure 32 Transient genetic programming market, 2021 - 2033 (USD million)
Figure 33 Other cell-engineering approaches market, 2021 - 2033 (USD million)
Figure 34 In Vivo Cell Therapy market: delivery modality outlook and key takeaways
Figure 35 In Vivo Cell Therapy market: delivery modality market share analysis
Figure 36 Viral vector-based market, 2021 - 2033 (USD million)
Figure 37 Lipid nanoparticle-based market, 2021 - 2033 (USD million)
Figure 38 Other non-viral delivery systems market, 2021 - 2033 (USD million)
Figure 39 Regional marketplace: Key takeaways
Figure 40 North America in vivo cell therapy market, country, 2021 - 2033 (USD million)
Figure 41 U.S. in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 42 Canada in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 43 Mexico in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 44 Europe in vivo cell therapy market, country, 2021 - 2033 (USD million)
Figure 45 UK in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 46 Germany in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 47 France in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 48 Italy in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 49 Spain in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 50 Denmark in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 51 Sweden in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 52 Norway in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 53 Asia Pacific in vivo cell therapy market, country, 2021 - 2033 (USD million)
Figure 54 Japan in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 55 China in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 56 India in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 57 Australia in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 58 Thailand in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 59 South Korea in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 60 Latin America in vivo cell therapy market, country, 2021 - 2033 (USD million)
Figure 61 Brazil in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 62 Argentina in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 63 MEA in vivo cell therapy market, country, 2021 - 2033 (USD million)
Figure 64 South Africa in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 65 Saudi Arabia in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 66 UAE in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 67 Kuwait in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Market formulation & validation
Figure 7 Market outlook
Figure 8 Segment snapshot
Figure 9 Competitive landscape snapshot
Figure 10 Parent market outlook
Figure 11 In Vivo Cell Therapy market driver analysis
Figure 12 In Vivo Cell Therapy market restraint analysis
Figure 13 In Vivo Cell Therapy market: Porter's five forces analysis
Figure 14 In Vivo Cell Therapy market: PESTLE analysis
Figure 15 In Vivo Cell Therapy market: therapeutic cell type outlook and key takeaways
Figure 16 In Vivo Cell Therapy market: therapeutic cell type market share analysis
Figure 17 T cells market, 2021 - 2033 (USD million)
Figure 18 NK cells market, 2021 - 2033 (USD million)
Figure 19 Myeloid cells market, 2021 - 2033 (USD million)
Figure 20 Other immune cells market, 2021 - 2033 (USD million)
Figure 21 In Vivo Cell Therapy market: therapeutic application outlook and key takeaways
Figure 22 In Vivo Cell Therapy market: therapeutic application market share analysis
Figure 23 Hematological malignancies market, 2021 - 2033 (USD million)
Figure 24 Solid tumors market, 2021 - 2033 (USD million)
Figure 25 Autoimmune diseases market, 2021 - 2033 (USD million)
Figure 26 Infectious diseases market, 2021 - 2033 (USD million)
Figure 27 Other therapeutic applications market, 2021 - 2033 (USD million)
Figure 28 In Vivo Cell Therapy market: in vivo cell-engineering outlook and key takeaways
Figure 29 In Vivo Cell Therapy market: in vivo cell-engineering market share analysis
Figure 30 Receptor engineering market, 2021 - 2033 (USD million)
Figure 31 Gene editing & gene modification market, 2021 - 2033 (USD million)
Figure 32 Transient genetic programming market, 2021 - 2033 (USD million)
Figure 33 Other cell-engineering approaches market, 2021 - 2033 (USD million)
Figure 34 In Vivo Cell Therapy market: delivery modality outlook and key takeaways
Figure 35 In Vivo Cell Therapy market: delivery modality market share analysis
Figure 36 Viral vector-based market, 2021 - 2033 (USD million)
Figure 37 Lipid nanoparticle-based market, 2021 - 2033 (USD million)
Figure 38 Other non-viral delivery systems market, 2021 - 2033 (USD million)
Figure 39 Regional marketplace: Key takeaways
Figure 40 North America in vivo cell therapy market, country, 2021 - 2033 (USD million)
Figure 41 U.S. in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 42 Canada in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 43 Mexico in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 44 Europe in vivo cell therapy market, country, 2021 - 2033 (USD million)
Figure 45 UK in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 46 Germany in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 47 France in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 48 Italy in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 49 Spain in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 50 Denmark in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 51 Sweden in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 52 Norway in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 53 Asia Pacific in vivo cell therapy market, country, 2021 - 2033 (USD million)
Figure 54 Japan in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 55 China in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 56 India in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 57 Australia in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 58 Thailand in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 59 South Korea in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 60 Latin America in vivo cell therapy market, country, 2021 - 2033 (USD million)
Figure 61 Brazil in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 62 Argentina in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 63 MEA in vivo cell therapy market, country, 2021 - 2033 (USD million)
Figure 64 South Africa in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 65 Saudi Arabia in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 66 UAE in vivo cell therapy market, 2021 - 2033 (USD million)
Figure 67 Kuwait in vivo cell therapy market, 2021 - 2033 (USD million)
Companies Mentioned
- Gilead Sciences, Inc.
- Legend Biotech
- Eli Lilly and Company
- CRISPR Therapeutics
- AbbVie Inc.
- Umoja Biopharma
- Ensoma, Inc.
- Intellia Therapeutics, Inc.
- Tessera Therapeutics
- AstraZeneca
- Valerio Therapeutics
- Johnson & Johnson
